From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring. Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.
Study Type
OBSERVATIONAL
National Taiwan University Hospita
Taipei, Taiwan
Novel biomarkers
Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;
Time frame: 1YEARS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.